Document:

EXHIBIT
4.2

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

LIFEMD,
INC.

 

	Warrant Shares: 1,500,000	 Initial Exercise Date: June 1, 2021

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [            ], a limited liability company
organized and existing under the laws of Delaware, or its assigns (the “Holder”) is entitled, upon the terms and subject
to the limitations on exercise and the conditions hereinafter set forth, including Section 1(e) hereof, at any time on or after the date
hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 1, 2024 (the “Termination
Date”) but not thereafter, to subscribe for and purchase from LifeMD, Inc., a corporation incorporated under the laws of the
State of Delaware (the “Company”), up to 1,500,000 shares of common stock
(“Common Stock”) of the Company, par value $0.01 (the “Warrant Shares”) subject to the provisions
of Section 1(e). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 1(b). This Warrant is being issued in connection with that certain Securities Purchase Agreement, dated as of May __, 2021
(the “Purchase Agreement”), among the Company and the Holder. Defined terms used herein but not otherwise defined
shall have the meanings assigned to them in the Purchase Agreement.

 

Section
1. Exercise.

 

a) Exercise
of Warrant. Subject to the terms and conditions hereof, including Section 1(e), this Warrant may be exercised by the Holder on any
day on or after the Initial Exercise Date, in whole or in part, by delivery (whether via facsimile or otherwise) of a written notice
(the “Notice of Exercise”) of the Holder’s election to exercise this Warrant. Within one (1) Trading Day following
an exercise of this Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount equal to the Exercise Price (as
defined below) in effect on the date of such exercise multiplied by the number of Warrant Shares as to which this Warrant was so exercised
(the “Aggregate Exercise Price”) in cash or via wire transfer of immediately available funds. The Holder shall not
be required to deliver the original of this Warrant in order to effect an exercise hereunder. Execution and delivery of a Notice of Exercise
with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original of this Warrant and issuance
of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of a Notice of Exercise
for all of the then-remaining Warrant Shares shall have the same effect as cancellation of the original of this Warrant after delivery
of the Warrant Shares in accordance with the terms hereof.

 

    	1

    	 

    

 

b) Exercise
Price. The exercise price per share of Common Stock under this Warrant shall be $12.00, subject to adjustment hereunder (the
“Exercise Price”).

 

c) Mechanics
                                            of Exercise.

 

i. Delivery
of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Company’s
transfer agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s or its designee’s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if
the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder
without volume or manner-of- sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in
the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
Aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate (but not Rule 144) purposes to have become the holder of record of the Warrant
Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that
payment of the aggregate Exercise Price is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
comprising the Standard Settlement Period following delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. As used herein, “Trading
Day” means a day on which the principal trading market of the Common Stock is open for trading.

 

    	2

    	 

    

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 1(c)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.

 

v. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as
may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto. The Company shall pay all Transfer Agent fees required for same- day processing of any Notice of Exercise and
all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.

 

vi. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

 

    	3

    	 

    

 

d) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 1 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any
other persons acting as a group together with the Holder or any of the Holder’s Affiliates (such persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 1(d), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange
Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 1(d) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the
Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. For purposes of this Section 1(d), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company’s most recent periodic or annual report filed with the SEC, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The
Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 1(d),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the
provisions of this Section 1(d) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 1(d) to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Warrant.

 

    	4

    	 

    

 

e) Vesting.
For the period beginning on the Initial Exercise Date and ending one year after this Warrant may only be exercised in respect of up to
500,000 shares of Common Stock. Thereafter so long as the Holder then owns, legally or beneficially, any of the Debentures, beginning
on the date that is 366 days from the Initial Exercise Date, this Warrant may be exercised in respect of up to an additional 500,000
shares of Common Stock, and beginning on the date that is 732 days from the Initial Exercise Date, this Warrant may be exercised for
up to an additional further 500,000 shares of Common Stock.

 

Section
2.Certain Adjustments.

 

a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity
equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock
issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues
by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall
be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any)
outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 2(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the
Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    	5

    	 

    

 

c) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another person or group of persons whereby such other person or group acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other person or other persons making or party to, or associated or affiliated with
the other persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 1(d) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
“Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 1(d) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the
survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and
the other Transaction Documents in accordance with the provisions of this Section 2(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from
and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the
“Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.

 

    	6

    	 

    

 

e) Calculations.
All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 2, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f) Notice
                                            to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which
the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the SEC pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.

 

    	7

    	 

    

 

Section
3.Transfer of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(d) hereof, this Warrant and all rights
hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant
at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the
form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.

 

b) New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

    	8

    	 

    

 

d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the transferee of this Warrant,
agrees in writing to be bound, with respect to this Warrant, by the provisions of the Transaction Documents that apply to the “Buyers.”

 

e) Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.

 

Section
4. Miscellaneous.

 

a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 1(c)(i), except as expressly set forth in Section 1.

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

d) Authorized
                                            Shares.

 

The
Company covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may
be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by
this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

    	9

    	 

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

e) Governing
Law; Jurisdiction. This Warrant shall be governed by and construed in accordance with the laws of the State of New York without regard
to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by
this Warrant shall be brought only in the federal courts of Southern District of New York. The parties to this Warrant hereby irrevocably
waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction
or venue or based upon forum non conveniens. The Company and Holder waive trial by jury. The prevailing party shall be entitled to recover
from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Warrant or any other agreement
delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be
deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of
law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any
other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served
in any suit, action or proceeding in connection with this Warrant by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any other manner permitted by law.

 

    	10

    	 

    

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.

 

g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h) Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt
requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery,
telegram, facsimile, or electronic mail addressed as set forth below or to such other address as such party shall have specified most
recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a)
upon hand delivery, upon electronic mail delivery, or delivery by facsimile, with accurate confirmation generated by the transmitting
facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such
notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal
business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier
service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses
for such communications shall be:

 

If
to the Company:

 

LifeMD,
Inc.

800
Third Avenue, Suite 2800

New York, New York

Attention:
Marc Benathen

E-Mail:
marc@lifemd.com

 

If
to the Holder:

 

[                       ]

 

_____________

 

_____________

e-mail:

 

    	11

    	 

    

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

l) Amendment;
Waivers. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.

 

********************

 

(Signature
Page Follows)

 

    	12

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	LIFEMD, INC.
	 	 	 
	 	By:	 
	 	Name: 
    	Justin
    Schreiber
	 	Title:
    	CEO

 

    	13

    	 

    

 

NOTICE
OF EXERCISE

 

TO:[
                                                  ]

 

(1)
The undersigned hereby elects to purchase                            Warrant
Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the
exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

 

 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

 

 

 
 

 

 

 

 

 

(3)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity:

Signature
of Authorized Signatory of Investing Entity: _____________________________________________________

Name
of Authorized Signatory: _______________________________________________________________________

Authorized
Signatory: ______________________________________________________________________________

Date:
___________________________________________________________________________________________

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name:

 

	 	 
	 	(Please
    Print)
	 	 
	Address:	 
	 	(Please
    Print)
	 	 
	Phone
    Number:	 
	 	 
	Email
    Address:	 
	 	 
	Dated:
    _______________, ________	 
	 	 
	Holder’s
    Signature: ______________________	 
	 	 
	Holder’s
    Address: ______________________Exhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated as of June 1, 2021 (the “Effective Date”),
by and between LIFEMD, inc., a corporation incorporated under the laws of the State of
Delaware (the “Company”), and each Buyer identified on the signature pages hereto (each, including its successors
and assigns, a “Buyer” and collectively, the “Buyers”).

 

WHEREAS,
the Buyers desire to purchase from Company, and the Company desires to sell and issue to the Buyers, upon the terms and subject to the
conditions contained herein, up to Fifteen Million and No/100 United States Dollars ($15,000,000) of senior secured redeemable debentures
(each in the form attached hereto as Exhibit A, the “Debenture(s)”), for a total purchase price of Fifteen
Million and No/100 United States Dollars ($15,000,000) (the “Purchase Price”);

 

WHEREAS,
the subsidiaries of the Company, LifeMD PR, LLC, a limited liability company organized and existing under the laws of Puerto Rico, and
LegalSimpli Software, LLC, a limited liability company organized and existing under the laws of Puerto Rico (each, a “Guarantor”
and together, the “Guarantors”), have agreed to deliver a guaranty agreement in favor of the Buyers, dated as of the
date hereof (the “Guaranty Agreement”);

 

WHEREAS,
the Company has agreed to secure all of the Company’s Obligations to Buyers under the Debentures, this Agreement and all other
Transaction Documents by granting to the Buyers an unconditional and continuing security interest in all of the assets and properties
of the Company, whether now existing or hereafter acquired, pursuant to a Security Agreement, dated as of the date hereof (in the form
attached hereto as Exhibit B-1, the “Company Security Agreement”);

 

WHEREAS,
the Guarantors have agreed to secure their Obligations to Buyers under the Guaranty Agreement by granting to the Buyers an unconditional
and continuing security interest in all of the assets and properties of the Guarantors, whether now existing or hereafter acquired, pursuant
to a Security Agreement, dated as of the date hereof (in the form attached hereto as Exhibit B-2, the “Guarantor Security
Agreement”, and together with the Company Security Agreement, the “Security Agreements”);and

 

WHEREAS,
the Buyers desire to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement warrants
to purchase up to 1,500,000 shares of the Common Stock (each in the form attached hereto as Exhibit C, the “Warrants”),
subject to adjustments, limitations and certain vesting provisions as provided therein.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants of the parties hereinafter expressed and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, each intending to be legally bound, agree
as follows:

 

    	 

     

    

 

ARTICLE
I

RECITALS,
EXHIBITS, SCHEDULES

 

The
foregoing recitals are true and correct and, together with the Schedules and Exhibits referred to hereafter, are hereby incorporated
into this Agreement by this reference.

 

ARTICLE
II

DEFINITIONS

 

For
purposes of this Agreement, except as otherwise expressly provided or otherwise defined elsewhere in this Agreement, or unless the context
otherwise requires, the capitalized terms in this Agreement shall have the meanings assigned to them in this Article as follows:

 

2.1
“Affiliate” means, with respect to a Person, any other Person directly or indirectly controlling, controlled by, or
under common control with, such Person at any time during the period for which the determination of affiliation is being made. For purposes
of this definition, the term “control,” “controlling,” “controlled” and words
of similar import, when used in this context, means, with respect to any Person, the possession, directly or indirectly, of the power
to direct, or cause the direction of, management policies of such Person, whether through the ownership of voting securities, by contract
or otherwise.

 

2.2
“Assets” means all of the properties and assets of the Person in question, as the context may so require, whether
real, personal or mixed, tangible or intangible, wherever located, whether now owned or hereafter acquired.

 

2.3
“Business Day” means any day other than a Saturday, Sunday or a legal holiday on which federal banks are authorized
or required to be closed for the conduct of commercial banking business.

 

2.4
“Claims” means any Proceedings, Judgments, Obligations, threats, losses, damages, deficiencies, settlements, assessments,
charges, costs and expenses of any nature or kind.

 

2.5
“Closing” shall have the meaning given to it in Section 4.2 hereof.

 

2.6
“Closing Date” shall have the meaning given to it in Section 4.2 hereof.

 

2.7
“Common Stock” means the common stock of the Company, par value $0.01 per share.

 

2.8
“Consent” means any consent, approval, order or authorization of, or any declaration, filing or registration with,
or any application or report to, or any waiver by, or any other action (whether similar or dissimilar to any of the foregoing) of, by
or with, any Person, which is necessary in order to take a specified action or actions, in a specified manner and/or to achieve a specific
result.

 

    	2

     

    

 

2.9
“Contract” means any written or oral contract, agreement, order or commitment of any nature whatsoever, including,
any sales order, purchase order, lease, sublease, license agreement, services agreement, loan agreement, mortgage, security agreement,
guarantee, management contract, employment agreement, consulting agreement, partnership agreement, shareholders agreement, buy-sell agreement,
option, warrant, debenture, subscription, call or put.

 

2.10
“Collateral” shall have the meaning given to it in the Security Agreements.

 

2.11
“Debenture(s)” shall have the meaning given to it in the preamble hereof.

 

2.12
“Effective Date” means the date so defined in the introductory paragraph of this Agreement.

 

2.13
“Encumbrance” means any lien, security interest, pledge, mortgage, easement, leasehold, assessment, tax, covenant,
restriction, reservation, conditional sale, prior assignment, or any other encumbrance, claim, burden or charge of any nature whatsoever.

 

2.14
“GAAP” means generally accepted accounting principles, methods and practices set forth in the opinions and pronouncements
of the Accounting Principles Board and the American Institute of Certified Public Accountants, and statements and pronouncements of the
Financial Accounting Standards Board, or of such other Person as may be approved by a significant segment of the U.S. accounting profession,
in each case as of the date or period at issue, and as applied in the U.S. to U.S. companies.

 

2.15
“Governmental Authority” means any foreign, federal, state or local government, or any political subdivision thereof,
or any court, agency or other body, organization, group, stock market or exchange exercising any executive, legislative, judicial, quasi-judicial,
regulatory or administrative function of government.

 

2.16
“Guarantors” shall have the meaning given to it in the recitals hereof.

 

2.17
“Guaranty Agreement” shall have the meaning given to it in the recitals hereof.

 

2.18
“Judgment” means any order, writ, injunction, fine, citation, award, decree, or any other judgment of any nature whatsoever
of any Governmental Authority.

 

2.19
“Law” means any provision of any law, statute, ordinance, code, constitution, charter, treaty, rule or regulation
of any Governmental Authority.

 

2.20
“Leases” means all leases for real or personal property.

 

2.21
“Material Adverse Effect” shall mean: (i) a material adverse change in, or a material adverse effect upon, the Assets,
business, prospects, properties, financial condition or results of operations of the Company; (ii) a material impairment of the ability
of the Company to perform any of its Obligations under any of the Transaction Documents; or (iii) a material adverse effect on: (A) any
material portion of the “Collateral” (as such term is defined in the Security Agreements); (B) the legality, validity, binding
effect or enforceability against the Company of any of the Transaction Documents; (C) the perfection or priority of any Encumbrance granted
to a Buyer under any Transaction Documents; or (D) the rights or remedies of the Buyers under any of the Transaction Documents. For purposes
of determining whether any of the foregoing changes, effects, impairments, or other events have occurred, such determination shall be
made by the Requisite Holders, in their sole, but reasonably exercised, discretion.

 

    	3

     

    

 

2.22
“Material Contract” shall mean any Contract to which the Company is a party or by which the Company or any of its
Assets are bound and which: (i) must be disclosed to any Governmental Authority or any other laws, rules or regulations of any Governmental
Authority; (ii) involves aggregate payments of One Million ($1,000,000) or more to or from the Company; (iii) involves delivery, purchase,
licensing or provision, by or to the Company, of any goods, services, assets or other items having a value (or potential value) over
the term of such Contract of One Million ($1,000,000) or more or is otherwise material to the conduct of the Company’s business
as now conducted and as contemplated to be conducted in the future; (iii) involves a contract in respect of material leasehold; (iv)
imposes any guaranty, surety or indemnification obligations on the Company; or (v) prohibits the Company from engaging in any business
or competing anywhere in the world.

 

2.23
“Obligation” means, now existing or in the future, any debt, liability or obligation of any nature whatsoever (including
any required performance of any covenants or agreements), whether secured, unsecured, recourse, nonrecourse, liquidated, unliquidated,
accrued, voluntary or involuntary, direct or indirect, absolute, fixed, contingent, ascertained, unascertained, known, unknown, whether
or not jointly owed with others, whether or not from time to time decreased or extinguished and later decreased, created or incurred,
or obligations existing or incurred under this Agreement, the Debentures or any other Transaction Documents, or any other agreement between
the Company and the Buyers, as such obligations may be amended, supplemented, converted, extended or modified from time to time.

 

2.24
“Ordinary Course of Business” means the ordinary course of business of the Person in question, consistent with past
custom and practice (including with respect to quantity, quality and frequency).

 

2.25
“Permit” means any license, permit, approval, waiver, order, authorization, right or privilege of any nature whatsoever,
granted, issued, approved or allowed by any Governmental Authority.

 

2.26
“Person” means any individual, sole proprietorship, joint venture, partnership, company, corporation, association,
cooperation, trust, estate, Governmental Authority, or any other entity of any nature whatsoever.

 

2.27
“Principal Trading Market” shall mean the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital
Market, the OTC Bulletin Board, the OTC Markets, the so-called OTC Pink Sheets, the NYSE Euronext or the New York Stock Exchange, whichever
is at the time the principal trading exchange or market for the Common Stock.

 

    	4

     

    

 

2.28
“Proceeding” means any demand, claim, suit, action, litigation, investigation, audit, study, arbitration, administrative
hearing, or any other proceeding of any nature whatsoever.

 

2.29
“Real Property” means any real estate, land, building, structure, improvement, fixture or other real property of any
nature whatsoever, including, but not limited to, fee and leasehold interests.

 

2.30
“Requisite Holders” means, individually or collectively, the holders of Debentures constituting sixty percent (60%)
or of the aggregate outstanding principal balance of all Debentures issued pursuant to this Agreement.

 

2.31
“SEC” shall mean the United States Securities and Exchange Commission.

 

2.32
“Securities” means, collectively, the Debentures, the Warrants, the Warrant Shares, or the terms of this Agreement
or any other Transaction Documents.

 

2.33
“Security Agreements” shall have the meaning given to it in the recitals hereof.

 

2.34
“Tax” means (i) any foreign, federal, state or local income, profits, gross receipts, franchise, sales, use, occupancy,
general property, real property, personal property, intangible property, transfer, fuel, excise, accumulated earnings, personal holding
company, unemployment compensation, social security, withholding taxes, payroll taxes, or any other tax of any nature whatsoever, (ii)
any foreign, federal, state or local organization fee, qualification fee, annual report fee, filing fee, occupation fee, assessment,
rent, or any other fee or charge of any nature whatsoever, or (iii) any deficiency, interest or penalty imposed with respect to any of
the foregoing.

 

2.35
“Tax Return” means any tax return, filing, declaration, information statement or other form or document required to
be filed in connection with or with respect to any Tax.

 

2.36
“Transaction Documents” means this Agreement any and all documents or instruments executed or to be executed the Company
in connection with this Agreement, including the Debentures, the Security Agreements, the Intellectual Property Security Agreement (as
defined in the Security Agreements) and the Warrants, together with all modifications, amendments, extensions, future advances, renewals,
and substitutions thereof.

 

2.37
“Warrant” shall have the meaning given to it in the recitals hereof.

 

2.38
“Warrant Shares” shall mean those shares of Common Stock issuable upon exercise of the Warrants to the holders thereof.

 

    	5

     

    

 

ARTICLE
III

INTERPRETATION

 

In
this Agreement, unless the express context otherwise requires: (i) the words “herein,” “hereof” and “hereunder”
and words of similar import refer to this Agreement as a whole and not to any particular provision of this Agreement; (ii) references
to the words “Article” or “Section” refer to the respective Articles and Sections of this Agreement, and references
to “Exhibit” or “Schedule” refer to the respective Exhibits and Schedules annexed hereto; (iii) references to
a “party” mean a party to this Agreement and include references to such party’s permitted successors and permitted
assigns; (iv) references to a “third party” mean a Person not a party to this Agreement; (v) references to the words “share”
or “shareholder”, if in reference to the Company, shall refer to “units” or “unitholder” respectively
and (v) the terms “dollars” and “$” means U.S. dollars; (vi) wherever the word “include,” “includes”
or “including” is used in this Agreement, it will be deemed to be followed by the words “without limitation”.

 

ARTICLE
IV

PURCHASE
AND SALE OF DEBENTURES AND WARRANTS

 

4.1
Purchase and Sale of Debentures and Warrants. Subject to the satisfaction (or waiver) of the terms and conditions of this Agreement,
each Buyer agrees to purchase, at the Closing, and the Company agrees to sell and issue to each Buyer, at the Closing, in exchange for
such Buyer’s portion of the Purchase Price, Debentures and Warrants in the amounts, set forth on such Buyer’s signature page
hereto.

 

4.2
Closing. The closing (the “Closing”) of the purchase and sale of the Debentures and Warrants shall take place
on or following the Effective Date, subject to satisfaction of the conditions to the Closing set forth in this Agreement (the “Closing
Date”), through the use of overnight mails and subject to customary escrow instructions from Buyers and their respective counsel,
or in such other manner as is mutually agreed to by the Company and the Buyers.

 

4.3
Form of Payment. Subject to the satisfaction of the terms and conditions of this Agreement, on the Closing Date: (i) each Buyer
shall deliver to the Company, to a Company account designated by the Company, their respective portion of the Purchase Price on such
Buyer’s signature page to this Agreement, in the form of wire transfers of immediately available U.S. dollars; and (ii) the Company
shall deliver to each Buyer the Securities which such Buyer is purchasing hereunder at the Closing, duly executed on behalf of the Company,
together with any other documents required to be delivered pursuant to this Agreement.

 

ARTICLE
V

BUYERS’
REPRESENTATIONS AND WARRANTIES

 

Each
Buyer represents and warrants to the Company, that:

 

5.1
Investment Purpose. Such Buyer is acquiring the Securities for its own account for investment only and not with a view towards,
or for resale in connection with, the public sale or distribution thereof.

 

    	6

     

    

 

5.2
Accredited Buyer Status. Such Buyer is an “accredited investor” as that term is defined in Rule 501 of Regulation
D, as promulgated under the Securities Act of 1933.

 

5.3
Reliance on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of such Buyer to acquire
the Securities.

 

5.4
Information. Such Buyer and its advisors, if any, have been furnished with all materials they have requested relating to the business,
finances and operations of the Company and information such Buyer deemed material to making an informed investment decision regarding
its purchase of the Securities. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company
and its management. Neither such inquiries, nor any materials provided to such Buyer, nor any other due diligence investigations conducted
by such Buyer or its advisors, if any, or its representatives, shall modify, amend or affect such Buyer’s right to fully rely on
the Company’s representations and warranties contained in Article VI below. Such Buyer understands that its investment in the Securities
involves a high degree of risk. Such Buyer is in a position regarding the Company, which, based upon economic bargaining power, enabled
and enables such Buyer to obtain information from the Company in order to evaluate the merits and risks of this investment. Such Buyer
has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect
to its acquisition of the Securities.

 

5.5
No Governmental Review. Such Buyer understands that no United States federal or state Governmental Authority has passed on or
made any recommendation or endorsement of the Securities, or the fairness or suitability of the investment in the Securities, nor have
such Governmental Authorities passed upon or endorsed the merits of the offering of the Securities.

 

5.6
Authorization, Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of such Buyer
and is a valid and binding agreement of such Buyer, enforceable in accordance with its terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws
relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

    	7

     

    

 

ARTICLE
VI

REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

To
induce each Buyer to purchase the Securities, the Company make the following representations and warranties to each Buyer, each of which
shall be true and correct in all respects as of the date of hereof, and which shall survive the execution and delivery of this Agreement:

 

6.1
Subsidiaries. A list of all of the Company’s Subsidiaries, direct and indirect, is set forth in Schedule 6.1 hereto.

 

6.2
Organization. The Company is a corporation, duly incorporated, validly existing and in good standing under the Laws of the State
of Delaware, and has the full power and authority and all necessary certificates, licenses, approvals and Permits to: (i) enter into
and execute this Agreement and the Transaction Documents and to perform all of its Obligations hereunder and thereunder; and (ii) own
and operate its Assets and properties and to conduct and carry on its business as and to the extent now conducted. The Company is duly
qualified to transact business and is in good standing as a foreign corporation in each jurisdiction where the character of its business
or the ownership or use and operation of its Assets or properties requires such qualification. The exact legal name of the Company is
as set forth in the preamble to this Agreement.

 

6.3
Authority and Approval of Agreement; Binding Effect. The execution and delivery by the Company of this Agreement and the Transaction
Documents, and the performance by the Company of all of its Obligations hereunder and thereunder, including the issuance of the Securities,
have been duly and validly authorized and approved by the Company and its board of directors pursuant to all applicable Laws and no other
action or Consent on the part of the Company or its board of directors is necessary or required to execute this Agreement and the Transaction
Documents, consummate the transactions contemplated herein and therein, perform all Obligations hereunder and thereunder, or to issue
the Securities. This Agreement and each of the Transaction Documents have been duly and validly executed by the Company (and the officer
executing this Agreement and all such other Transaction Documents is duly authorized to act and execute same on behalf of the Company)
and constitute the valid and legally binding agreements of the Company, enforceable against the Company in accordance with their respective
terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights
and remedies.

 

6.4
Capitalization. The authorized capital stock or other capitalization of the Company, as applicable, is set forth in Schedule
6.4 attached hereto. All of such outstanding shares or other securities of the Company are validly issued, fully paid and non-assessable
and have been issued in compliance with all foreign, federal and state securities laws and none of such outstanding shares or other securities
were issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. The Common Stock is currently
quoted on the Company’s Principal Trading Market under the trading symbol “LFMD”. The Company has received no notice,
either oral or written, with respect to the continued eligibility of the Common Stock for quotation on the Principal Trading Market,
and the Company has maintained all requirements on its part for the continuation of such quotation. The Company has furnished to each
Buyer true, complete and correct copies of the Company’s articles of incorporation (including any certificates of designation,
as applicable) (the “Organizational Documents”). Except for the Organizational Documents or as disclosed in
the Public Documents, there are no other shareholder agreements, voting agreements or other Contracts of any nature or kind that restrict,
limit or in any manner impose Obligations on the governance of the Company.

 

    	8

     

    

 

6.5
No Conflicts; Consents and Approvals. The execution, delivery and performance of this Agreement and the Transaction Documents,
and the consummation of the transactions contemplated hereby and thereby, including the issuance of any of the Securities, will not:
(i) constitute a violation of or conflict with the Organizational Documents of the Company; (ii) constitute a violation of, or a default
or breach under (either immediately, upon notice, upon lapse of time, or both), or conflicts with, or gives to any other Person any rights
of termination, amendment, acceleration or cancellation of, any provision of any Contract to which the Company is a party or by which
any of its Assets or properties may be bound; (iii) constitute a violation of, or a default or breach under (either immediately, upon
notice, upon lapse of time, or both), or conflicts with, any Judgment; or (iv) constitute a violation of, or conflict with, any Law (including
United States federal and state securities Laws). Except as specifically contemplated by this Agreement, the Company is not required
to obtain any Consent of, from, or with any Governmental Authority, or any other Person, in order for it to execute, deliver or perform
any of its Obligations under this Agreement or the Transaction Documents in accordance with the terms hereof or thereof, or to issue
and sell the Securities in accordance with the terms hereof. All Consents which the Company is required to obtain pursuant to the immediately
preceding sentence have been obtained or effected on or prior to the date hereof.

 

6.6
Issuance of Securities. The Securities are duly authorized and, upon issuance in accordance with the terms hereof, shall be duly
issued, fully paid and non-assessable, and free from all Encumbrances with respect to the issue thereof, and will be issued in compliance
with all applicable United States federal and state securities Laws.

 

6.7
Public Documents. The Common Stock of the Company is registered pursuant to Section 12 of the Exchange Act and the Company is
subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act. The Company has timely filed all reports, schedules,
forms, statements and other documents required to be filed by it with the SEC, the Principal Trading Market, or any other Governmental
Authority, as applicable (all of the foregoing filed within the two (2) years preceding the date hereof or amended after the date hereof
and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, being
hereinafter referred to as the “Public Documents”). The Company is current with its filing obligations with the SEC,
the Principal Trading Market, or any other Governmental Authority, as applicable, and all Public Documents have been filed on a timely
basis by the Company. The Company represents and warrants that true and complete copies of the Public Documents are available on the
SEC website (www.sec.gov) at no charge to Buyers, and each Buyer acknowledges that it may retrieve all Public Documents from such websites
and such Buyer’s access to such Public Documents through such website shall constitute delivery of the Public Documents to such
Buyer; provided, however, that if a Buyer is unable to obtain any of such Public Documents from such websites at no charge, as a result
of such websites not being available or any other reason beyond Buyer’s control, then upon request from such Buyer, the Company
shall deliver to such Buyer true and complete copies of such Public Documents. None of the Public Documents, at the time they were filed
with the SEC, its Principal Trading Market, or other Governmental Authority, as applicable, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading. None of the statements made in any such Public Documents is, or has
been, required to be amended or updated under applicable law (except for such statements as have been amended or updated in subsequent
filings prior the date hereof, which amendments or updates are also part of the Public Documents). As of their respective dates, the
consolidated financial statements of the Company and its Subsidiaries included in the Public Documents complied in all material respects
with applicable accounting requirements and any published rules and regulations of the SEC and its Principal Trading Market with respect
thereto.

 

    	9

     

    

 

6.8
Absence of Certain Changes. Since the date of the most recent of the Financial Statements, none of the following have occurred:

 

(a)
There has been no event or circumstance of any nature whatsoever that has resulted in, or could reasonably be expected to result in,
a Material Adverse Effect; or

 

(b)
Any transaction, event, action, development, payment, or any other matter of any nature whatsoever entered into by the Company other
than in the Company’s Ordinary Course of Business.

 

6.9
Absence of Litigation or Adverse Matters. Except as set forth in the Public Documents, no condition, circumstance, event, agreement,
document, instrument, restriction, litigation or Proceeding (or threatened litigation or Proceeding or basis therefor) exists which:
(i) could adversely affect the validity or priority of the Encumbrances granted to the Buyers under the Transaction Documents; (ii) could
adversely affect the ability of the Company to perform its Obligations under the Transaction Documents; (iii) would constitute a default
under any of the Transaction Documents; (iv) would constitute such a default with the giving of notice or lapse of time or both; or (v)
would constitute or give rise to a Material Adverse Effect. In addition: (vi) there is no Proceeding before or by any Governmental Authority
or any other Person, pending, or the best of Company’s knowledge, threatened or contemplated by, against or affecting the Company,
its business or Assets; and (vii) there are no outstanding Judgments against or affecting the Company, its business or Assets.

 

6.10
Liabilities and Indebtedness of the Company. The Company does not have any Obligations of any nature whatsoever, except: (i) as
disclosed in the Financial Statements; or (ii) Obligations incurred in the Ordinary Course of Business since the date of the most recent
Financial Statements have a Material Adverse Effect; or (iii) Obligations owed to the Buyers.

 

6.11
Title to Assets. The Company has good and marketable title to, or a valid leasehold interest in, all of its Assets which are material
to the business and operations of the Company as presently conducted, free and clear of all Encumbrances or restrictions on the transfer
or use of same. The Company’s Assets are in good operating condition and repair, ordinary wear and tear excepted, and are free
of any latent or patent defects which might impair their usefulness, and are suitable for the purposes for which they are currently used
and for the purposes for which they are proposed to be used.

 

    	10

     

    

 

6.12
Real Estate. Except as set forth on Schedule 6.12, the Company does not own any Real Property.

 

6.13
Compliance with Laws. To the knowledge of the Company and its officers, the Company is in full compliance with all Laws.

 

6.14
Intellectual Property. The Company owns or possesses adequate and legally enforceable rights or licenses to use all trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and all other intellectual property rights necessary to conduct its business as now conducted
(collectively, the “IP Rights”). All IP Rights, and any federal, state, local or foreign patent and trademark office,
or functional equivalent thereof where any such IP Rights may be filed or registered, is set forth in Schedule 6.14. All of the
IP Rights are owned by the Company, except for IP Rights licensed by the Company, which licensed IP Rights are specifically outlined
and described in Schedule 6.14.

 

6.15
Labor and Employment Matters. The Company is not involved in any labor dispute or, to the knowledge of the Company, is any such
dispute threatened. To the knowledge of the Company and its officers, none of the employees of the Company is a member of a union and
the Company believes that its relations with its employees are good. To the knowledge of the Company and its officers, the Company has
complied in all material respects with all Laws relating to employment matters, civil rights and equal employment opportunities.

 

6.16
Employee Benefit Plans. Except as disclosed to each Buyer in writing prior to the date hereof, the Company does not have and have
not ever maintained, and has no Obligations with respect to any employee benefit plans or arrangements, including employee pension benefit
plans, as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), multiemployer
plans, as defined in Section 3(37) of ERISA, employee welfare benefit plans, as defined in Section 3(1) of ERISA, deferred compensation
plans, stock option plans, bonus plans, stock purchase plans, hospitalization, disability and other insurance plans, severance or termination
pay plans and policies, whether or not described in Section 3(3) of ERISA, in which employees, their spouses or dependents of the Company
participate (collectively, the “Employee Benefit Plans”). To the Company’s knowledge, all Employee Benefit Plans
meet the minimum funding standards of Section 302 of ERISA, where applicable, and each such Employee Benefit Plan that is intended to
be qualified within the meaning of Section 401 of the Internal Revenue Code of 1986 is qualified. No withdrawal liability has been incurred
under any such Employee Benefit Plans and no “Reportable Event” or “Prohibited Transaction” (as such terms are
defined in ERISA), has occurred with respect to any such Employee Benefit Plans, unless approved by the appropriate Governmental Authority.
To the Company’s knowledge, the Company has promptly paid and discharged all Obligations arising under ERISA of a character which
if unpaid or unperformed might result in the imposition of an Encumbrance against any of its Assets or otherwise have a Material Adverse
Effect.

 

    	11

     

    

 

6.17
Tax Matters. The Company has made and timely filed all Tax Returns required by any jurisdiction to which it is subject, and each
such Tax Return has been prepared in compliance with all applicable Laws, and all such Tax Returns are true and accurate in all respects.
Except and only to the extent that the Company has set aside on its books provisions reasonably adequate for the payment of all unpaid
and unreported Taxes, the Company has timely paid all Taxes shown or determined to be due on such Tax Returns, except those being contested
in good faith, and the Company has set aside on its books provision reasonably adequate for the payment of all Taxes for periods subsequent
to the periods to which such Tax Returns apply. There are no unpaid Taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has withheld and paid all Taxes
to the appropriate Governmental Authority required to have been withheld and paid in connection with amounts paid or owing to any Person.
There is no Proceeding or Claim for refund now in progress, pending or threatened against or with respect the Company regarding Taxes.

 

6.18
Insurance. The Company is covered by valid, outstanding and enforceable policies of insurance which were issued to it by reputable
insurers of recognized financial responsibility, covering its properties, Assets and businesses against losses and risks normally insured
against by other corporations or entities in the same or similar lines of businesses as the Company and in coverage amounts which are
prudent and typically and reasonably carried by such other corporations or entities (the “Insurance Policies”). Such
Insurance Policies are in full force and effect, and all premiums due thereon have been paid. None of the Insurance Policies will lapse
or terminate as a result of the transactions contemplated by this Agreement.

 

6.19
Permits. The Company possesses all Permits necessary to conduct its business, and the Company has not received any notice of,
or is otherwise involved in any Proceedings relating to, the revocation or modification of any such Permits. All such Permits are valid
and in full force and effect.

 

6.20
Business Locations. The Company has no offices or places of business other than as identified on Schedule 6.20 and the
Company’s principal places of business and chief executive offices are indicated on Schedule 6.20. All books and records
of the Company and other material Assets of the Company are held or located at the location indicated on Schedule 6.20.

 

6.21
Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii) access to Assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for Assets is compared with the existing Assets at reasonable intervals and appropriate action is taken with respect to
any differences..

 

    	12

     

    

 

6.22
Brokerage Fees. There is no Person acting on behalf of the Company who is entitled to or has any claim for any brokerage or finder’s
fee or commission in connection with the execution of this Agreement or the consummation of the transactions contemplated hereby.

 

6.23
No General Solicitation. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection
with the offer or issuance of the Securities.

 

6.24
No Integrated Offering. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require
registration of the Securities under the Securities Act or cause this offering of such securities to be integrated with prior offerings
by the Company for purposes of the Securities Act.

 

6.25
Private Placement. No registration under the Securities Act or the laws, rules or regulation of any other governmental authority
is required for the issuance of the Securities.

 

ARTICLE
VII

COVENANTS

 

7.1
Negative Covenants.

 

(a)
Indebtedness. So long as any Buyer owns, legally or beneficially, any of the Debentures, the Company shall not without the prior
written consent of the Requisite Holders, either directly or indirectly, create, assume, incur or have outstanding any indebtedness for
borrowed money of any nature or kind (including purchase money indebtedness), or become liable, whether as endorser, guarantor, surety
or otherwise, for any Obligation of any other Person, except for: (i) the Debentures; (ii) Obligations disclosed in the financial statements
provided to the Buyers as of the Effective Date; and (iii) Obligations for accounts payable not overdue by more than 90 days, other than
for money borrowed, incurred in the Ordinary Course of Business of the Company.

 

(b)
Encumbrances. So long as any Buyer owns, legally or beneficially, any of the Debentures, the Company shall not, either directly
or indirectly, create, assume, incur or suffer or permit to exist any Encumbrance upon any Asset of the Company, whether owned at the
date hereof or hereafter acquired other than Permitted Liens (as defined in the Security Agreements).

 

    	13

     

    

 

(c)
Transfer; Merger. So long as any Buyer owns, legally or beneficially, any of the Debentures, the Company shall not, either directly
or indirectly, permit or enter into any transaction involving a “Change of Control” (as hereinafter defined), or any other
merger, consolidation, sale, transfer, license, Lease, Encumbrance or other disposition of its Assets, except for the sale, lease or
licensing of property or Assets of the Company in the Ordinary Course of Business of the Company. For purposes of this Agreement, the
term “Change of Control” shall mean (i) any sale, conveyance, assignment or other transfer, directly or indirectly,
of any ownership interest of the Company which results in any change in the identity of the individuals or entities previously having
the power to direct, or cause the direction of, the management and policies of the Company, or the grant of a security interest in any
ownership interest of any Person directly or indirectly controlling the Company, which could result in a change in the identity of the
individuals or entities previously having the power to direct, or cause the direction of, the management and policies of the Company
or (ii) at any time, any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Exchange
Act), other than any Buyer or Affiliate thereof, shall become, or obtain rights (whether by means of warrants, options or otherwise)
to become, the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act), directly or indirectly,
of 35% or more of the ordinary voting power for the election of directors of the Company (determined on a fully diluted basis).

 

(f)
Business Activities; Change of Legal Status and Organizational Documents. The Company shall not: (i) engage in any line of business
other than the businesses engaged in as of the Effective Date and business reasonably related thereto; (ii) change its name, organizational
identification number (if applicable), its type of organization, its jurisdiction of organization or other legal structure; or (iii)
permit its Certificate of Incorporation, Bylaws or other organizational documents to be amended or modified in any way materially adverse
to the interests of the Buyers.

 

(g)
Transactions with Affiliates. The Company shall not enter into any transaction with any of its Affiliates, officers, directors,
employees or other insiders, except in the Ordinary Course of Business and upon fair and reasonable terms that are no less favorable
to the Company than it would obtain in a comparable arm’s length transaction with a Person not an Affiliate of the Company

 

(h)
Restricted Payments. The Company shall not make any payment or prepayment of principal of, premium, if any, or interest on, or
redemption, purchase, retirement, defeasance (including in-substance or legal defeasance), sinking fund or similar payment with respect
to, any indebtedness, pay any earn-out payment, seller debt or deferred purchase price payments, declare or pay any dividend on, or make
any payment on account of, or set apart assets for a sinking or other analogous fund for, the purchase, redemption, defeasance, retirement
or other acquisition of, any capital stock, whether now or hereafter outstanding, or make any other distribution in respect thereof,
either directly or indirectly, whether in cash or property.

 

(i)
Investments. The Company shall not make any advance, loan, extension of credit (by way of guarantee or otherwise) or capital contribution
to, or purchase any capital stock, bonds, notes, debentures or other debt securities of, or any assets constituting a business unit of,
or make any other investment in, any Person, excluding, for the avoidance of doubt, (x) investments into the Company’s Subsidiaries,
LifeMD PR, LLC and LegalSimpli Software, LLC, and (y) accounts receivable arising in the ordinary course of business, except extensions
of trade credit in the ordinary course of business and investments in cash and cash equivalents.

 

    	14

     

    

 

7.2
Affirmative Covenants.

 

(a)
Corporate Existence. The Company shall at all times preserve and maintain its: (i) existence and good standing in the jurisdiction
of its organization; and (ii) its qualification to do business and good standing in each jurisdiction where the nature of its business
makes such qualification necessary, and shall at all times continue as a going concern in the business which the Company is presently
conducting.

 

(b)
Tax Liabilities. The Company shall at all times pay and discharge all Taxes upon, and all Claims (including claims for labor,
materials and supplies) against any Company or any of its properties or Assets, before the same shall become delinquent and before penalties
accrue thereon, unless and to the extent that the same are being contested in good faith by appropriate proceedings and for which adequate
reserves in accordance with GAAP are being maintained.

 

(c)
Notice of Proceedings. The Company shall, promptly, but not more than five (5) Business Days after knowledge thereof shall have
come to the attention of any officer of the Company, give written notice to the Buyers of all threatened or pending Proceedings before
any Governmental Authority or otherwise affecting the Company or any of its Assets.

 

(d)
Material Adverse Effect. The Company shall give immediate written notice to the Buyers of any event, circumstance, fact or other
matter that could in any way have or be reasonably expected to have a Material Adverse Effect.

 

(e)
Maintain Property. The Company shall at all times maintain, preserve and keep all of its Assets in good repair, working order
and condition, normal wear and tear excepted, and shall from time to time, as the Company deems appropriate in its reasonable judgment,
make all needful and proper repairs, renewals, replacements, and additions thereto so that at all times the efficiency thereof shall
be fully preserved and maintained.

 

(f)
Maintain Insurance. The Company shall at all times insure and keep insured with insurance companies reasonably acceptable to the
Requisite Holders, all insurable property owned by the Company which is of a character usually insured by companies similarly situated
and operating like properties, against loss or damage from environmental, fire and such other hazards or risks as are customarily insured
against by companies similarly situated and operating like properties; and shall similarly insure employers’, public and professional
liability risks.

 

(g)
ERISA Liabilities; Employee Plans. The Company shall: (i) keep in full force and effect any and all Employee Plans which are presently
in existence or may, from time to time, come into existence under ERISA, and not withdraw from any such Employee Plans, unless such withdrawal
can be effected or such Employee Plans can be terminated without liability to the Company; (ii) make contributions to all of such Employee
Plans in a timely manner and in a sufficient amount to comply with the standards of ERISA, including the minimum funding standards of
ERISA; (iii) comply with all material requirements of ERISA which relate to such Employee Plans; (iv) notify Buyers immediately upon
receipt by the Company of any notice concerning the imposition of any withdrawal liability or of the institution of any Proceeding or
other action which may result in the termination of any such Employee Plans or the appointment of a trustee to administer such Employee
Plans; (v) promptly advise Buyers of the occurrence of any “Reportable Event” or “Prohibited Transaction” (as
such terms are defined in ERISA), with respect to any such Employee Plans; and (vi) amend any Employee Plan that is intended to be qualified
within the meaning of Section 401 of the Internal Revenue Code of 1986 to the extent necessary to keep the Employee Plan qualified, and
to cause the Employee Plan to be administered and operated in a manner that does not cause the Employee Plan to lose its qualified status.

 

    	15

     

    

 

(h)
Reporting Status; Listing. So long as any Buyer owns, legally or beneficially, any of the Securities, the Company shall: (i) file
in a timely manner all reports required to be filed under the Securities Act, the Exchange Act or any securities Laws and regulations
thereof applicable to the Company of any state of the United States, or by the rules and regulations of the Principal Trading Market;
(ii) not terminate its status as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules and
regulations thereunder would otherwise permit such termination; (iii) if required by the rules and regulations of the Principal Trading
Market, promptly secure the listing of any shares of Common Stock issuable to a Buyer under any of the Transaction Documents upon the
Principal Trading Market (subject to official notice of issuance) and, take all reasonable action under its control to maintain the continued
listing, quotation and trading of its Common Stock (including, without limitation, any shares of Common Stock issuable to Buyers under
any of the Transaction Documents) on the Principal Trading Market, and the Company shall comply in all respects with the Company’s
reporting, filing and other Obligations under the bylaws or rules of the Principal Trading Market, the Financial Industry Regulatory
Authority, Inc. and such other Governmental Authorities, as applicable and (iv) within five (5) days of filing, provide to each Buyer
copies of all periodic and other reports, proxy statements and other materials filed by the Company with the SEC, any Governmental Authority
succeeding to any or all of the functions of the SEC or with any national securities exchange, or distributed to its shareholders, as
the case may be.

 

7.3
Share Reserve. The Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance,
such number of shares of Common Stock as shall be necessary to effect the issuance of the Warrant Shares upon exercise of the Warrants
(collectively, the “Share Reserve”). The Company represents that it has sufficient authorized and unissued shares
of Common Stock available to create the Share Reserve after considering all other commitments that may require the issuance of Common
Stock. The Company shall take all action reasonably necessary to at all times have authorized, and reserved for the purpose of issuance,
such number of shares of Common Stock as shall be necessary to effect the full exercise of the Warrants.

 

7.4
Proceeds of the Company’s At-The-Market Offerings. Until such time as the Obligations shall have been paid in full, the
Company shall apply thirty-five percent (35%) of the gross proceeds received by the Company from At-The-Market offerings of its Common
Stock to partial redemptions of each Debenture on a pro rata basis.

 

7.5
Use of Proceeds. Borrower shall use the proceeds of the Debentures as working capital and to fund its general corporate purposes.

 

    	16

     

    

 

ARTICLE
VIII

CONDITIONS
PRECEDENT TO THE COMPANY’S OBLIGATIONS TO SELL

 

The
obligation of the Company hereunder to issue and sell the Securities to the Buyers at the Closing is subject to the satisfaction, at
or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit
and may be waived by the Company at any time in its sole discretion:

 

8.1
Each Buyer shall have executed the Transaction Documents and delivered them to the Company.

 

8.2
The representations and warranties of each Buyer shall be true and correct in all material respects as of the date when made and as of
the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and each Buyer
shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this
Agreement to be performed, satisfied or complied with by such Buyer at or prior to the Closing Date.

 

8.3
The Company shall have received such certificates, confirmations, resolutions, acknowledgements or other documentation necessary or advisable
from all applicable Governmental Authorities, as the Company may require in order to evidence such Governmental Authorities’ approval
of this Agreement, the Transaction Documents and the purchase of the Debentures and Warrants contemplated hereby.

 

ARTICLE
IX

CONDITIONS
PRECEDENT TO THE BUYERS’ OBLIGATIONS TO PURCHASE

 

The
obligation of each Buyer hereunder to purchase the Debentures and Warrants at the Closing is subject to the satisfaction, at or before
the Closing Date, of each of the following conditions (in addition to any other conditions precedent elsewhere in this Agreement), provided
that these conditions are for such Buyer’s sole benefit and may be waived by such Buyer at any time in its sole discretion:

 

9.1
The Company shall have executed and delivered the Transaction Documents and delivered the same to each Buyer.

 

9.2
The representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any of
such representations and warranties are already qualified as to materiality in Article VI above, in which case, such representations
and warranties shall be true and correct in all respects without further qualification) as of the date when made and as of the Closing
Date as though made at that time (except for representations and warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to
be performed, satisfied or complied with by the Company at or prior to the Closing Date.

 

    	17

     

    

 

9.3
The Company shall have executed and delivered to each Buyer an officer’s certificate, certified as true, complete and correct by
an officer of the Company, in substance and form required by the Requisite Holders, which closing certificate shall include and attach
as exhibits: (i) a true copy of a certificate of good standing evidencing the incorporation and good standing of Company from the Secretary
of State of Delaware; (ii) the Company’s Organizational Documents; and (iii) copies of the resolutions of the board of directors
of the Company as adopted by the Company’s board of directors, in a form acceptable to the Requisite Holders.

 

9.4
The Company shall have delivered UCC financing statements in form and substance reasonably satisfactory to the Requisite Holders for
filing with the appropriate filing offices to perfect the Secured Parties’ (as defined in the Security Agreements) liens in and
to the Collateral in which a security interest may be perfected by the filing of financing statements.

 

9.5
The Company shall have delivered certified copies, dated as of a recent date, of customary lien searches with respect to the Company
accompanied by written evidence (including any UCC termination statements) that the liens indicated in any such financing statements
either constitute Permitted Liens (as defined in the Security Agreements) or have been or will be terminated or released.

 

9.6
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect.

 

9.7
The Company shall have executed such other agreements, certificates, confirmations or resolutions as the Buyers may require to consummate
the transactions contemplated by this Agreement and the Transaction Documents, including a closing statement and joint disbursement instructions
as may be required by Buyers.

 

ARTICLE
X

INDEMNIFICATION

 

10.1
Company’s Obligation to Indemnify. In consideration of each Buyer’s execution and delivery of this Agreement and acquiring
the Securities hereunder, and in addition to all of the Company’s other obligations under this Agreement, the Company hereby agrees
to defend and indemnify each Buyer and its Affiliates and subsidiaries and their respective directors, officers, employees, agents and
representatives, and the successors and assigns of each of them (collectively, the “Buyer Indemnified Parties”) and
Company does hereby agree to hold the Buyer Indemnified Parties harmless, from and against any and all Claims made, brought or asserted
against the Buyer Indemnified Parties, or any one of them, and Company hereby agrees to pay or reimburse the Buyer Indemnified Parties
for any and all Claims payable by any of the Buyer Indemnified Parties to any Person, including reasonable attorneys’ and paralegals’
fees and expenses, court costs, settlement amounts, and costs of investigation, as a result of, or arising out of, or relating to: (i)
any material misrepresentation or breach of any representation or warranty made by the Company in this Agreement, the Transaction Documents
or any other certificate, instrument or document contemplated hereby or thereby; (ii) any material breach of any covenant, agreement
or Obligation of the Company contained in this Agreement, the Transaction Documents or any other certificate, instrument or document
contemplated hereby or thereby; or (iii) any Claims brought or made against the Buyer Indemnified Parties, or any one of them, by a third
party and arising out of or resulting from the execution, delivery, performance or enforcement of this Agreement, the Transaction Documents
or any other instrument, document or agreement executed pursuant hereto or thereto.

 

    	18

     

    

 

ARTICLE
XI

MISCELLANEOUS

 

11.1 Notices.
All notices of request, demand and other communications hereunder shall be addressed to the parties as follows:

 

	If
    to the Company:	LifeMD,
    Inc.
	 	800
    Third Avenue, Suite 2800
	 	New
    York, New York
	 	Attention:
    Marc Benathen
	 	E-Mail:
    marc@lifemd.com
	 	 
	With
    a copy to:	Lucosky
    Brookman LLP
	(which
    shall not constitute notice)	101
    Wood Avenue South, 5th Floor
	 	Woodbridge,
    NJ 08830
	 	Attn:
    Seth A. Brookman, Esq.
	 	E-Mail:
    sbrookman@lucbro.com
	 	 
	If
    to a Buyer:	To
    the address set forth on such Buyer’s signature  page hereto.

 

unless
the address is changed by the party by like notice given to the other parties. Notice shall be in writing and shall be deemed delivered:
(i) if mailed by certified mail, return receipt requested, postage prepaid and properly addressed to the address below, then three (3)
business days after deposit of same in a regularly maintained U.S. Mail receptacle; or (ii) if mailed by Federal Express, UPS or other
nationally recognized overnight courier service, next business morning delivery, then one (1) business day after deposit of same in a
regularly maintained receptacle of such overnight courier; or (iii) if hand delivered, then upon hand delivery thereof to the address
indicated on or prior to 5:00 p.m., EST, on a business day. Any notice hand delivered after 5:00 p.m., EST, shall be deemed delivered
on the following business day. Notwithstanding the foregoing, notice, consents, waivers or other communications referred to in this Agreement
may be sent by facsimile, e-mail, or other method of delivery, but shall be deemed to have been delivered only when the sending party
has confirmed (by reply e-mail or some other form of written confirmation from the receiving party) that the notice has been received
by the other party.

 

    	19

     

    

 

11.2
Entire Agreement. This Agreement and the other Transaction Documents: (i) are valid, binding and enforceable against the Company
and Buyers in accordance with its provisions and no conditions exist as to their legal effectiveness; (ii) constitute the entire agreement
among the parties; and (iii) are the final expression of the intentions of the Company and Buyers. No promises, either expressed or implied,
exist between the Company and Buyers unless contained herein or in the Transaction Documents. This Agreement and the Transaction Documents
supersede all negotiations, representations, warranties, commitments, offers, contracts (of any kind or nature, whether oral or written)
prior to or contemporaneous with the execution hereof.

 

11.3
Amendments; Waivers. No amendment, modification, termination, discharge or waiver of any provision of this Agreement or of the
Transaction Documents shall in any event be effective unless the same shall be in writing and signed by the parties.

 

11.4
WAIVER OF JURY TRIAL. BUYERS AND THE COMPANY, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, EACH KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVES, IRREVOCABLY, THE RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING BASED HEREON, OR ARISING
OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, ANY TRANSACTION DOCUMENT OR ANY OF THE OBLIGATIONS HEREUNDER, THE COLLATERAL, OR
ANY OTHER AGREEMENT EXECUTED OR CONTEMPLATED TO BE EXECUTED IN CONJUNCTION WITH THIS AGREEMENT, OR ANY COURSE OF CONDUCT OR COURSE OF
DEALING IN WHICH BUYERS AND THE COMPANY ARE ADVERSE PARTIES.

 

11.5
MANDATORY FORUM SELECTION. THE COMPANY AND BUYERS IRREVOCABLY AGREE THAT ANY DISPUTE ARISING UNDER, RELATING TO, OR IN CONNECTION
WITH, DIRECTLY OR INDIRECTLY, THIS AGREEMENT OR RELATED TO ANY MATTER WHICH IS THE SUBJECT OF OR INCIDENTAL TO THIS AGREEMENT ANY OTHER
TRANSACTION DOCUMENT (WHETHER OR NOT SUCH CLAIM IS BASED UPON BREACH OF CONTRACT OR TORT) SHALL BE SUBJECT TO THE EXCLUSIVE JURISDICTION
AND VENUE OF THE STATE AND/OR FEDERAL COURTS LOCATED IN THE SOUTHERN DISTRICT OF NEW YORK. THIS PROVISION IS INTENDED TO BE A “MANDATORY”
FORUM SELECTION CLAUSE AND GOVERNED BY AND INTERPRETED CONSISTENT WITH NEW YORK LAW. EACH OF THE COMPANY AND BUYERS HEREBY CONSENTS TO
THE EXCLUSIVE JURISDICTION AND VENUE OF ANY STATE OR FEDERAL COURT HAVING ITS SITUS IN SAID DISTRICT, AND WAIVES ANY OBJECTION BASED
ON FORUM NON CONVENIENS.

 

11.6
Binding Effect. This Agreement shall become effective upon execution by the Company and Buyers.

 

11.7
Governing Law. This Agreement and all other Transaction Documents shall be delivered and accepted in and shall be deemed to be
contracts made under and governed by the internal laws of the State of New York, and for all purposes shall be construed in accordance
with the laws of such State, without giving effect to the choice of law provisions of such State.

 

    	20

     

    

 

11.8
Enforceability. Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement shall be prohibited by, unenforceable or invalid under any jurisdiction,
such provision shall as to such jurisdiction, be severable and be ineffective to the extent of such prohibition or invalidity, without
invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

11.15
Interpretation. If any provision in this Agreement requires judicial or similar interpretation, the judicial or other such body
interpreting or construing such provision shall not apply the assumption that the terms hereof shall be more strictly construed against
one party because of the rule that an instrument must be construed more strictly against the party which itself or through its agents
prepared the same. The parties hereby agree that all parties and their agents have participated in the preparation hereof equally.

 

11.18
Gender and Use of Singular and Plural. All pronouns shall be deemed to refer to the masculine, feminine, neuter, singular or plural,
as the identity of the party or parties or their personal representatives, successors and assigns may require.

 

11.19
Execution. This Agreement may be executed in one or more counterparts, all of which taken together shall be deemed and considered
one and the same Agreement, and same shall become effective when counterparts have been signed by each party and each party has delivered
its signed counterpart to the other party. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf’ format file or other similar format file, such signature shall be deemed an original for all purposes and shall
create a valid and binding obligation of the party executing same with the same force and effect as if such facsimile or “.pdf’
signature page was an original thereof.

 

11.20
Headings. The article and section headings contained in this Agreement are inserted for convenience only and shall not affect
in any way the meaning or interpretation of the Agreement.

 

11.21
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

[signature
pages follow]

 

    	21

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date and year set forth above.

 

COMPANY:

 

LIFEMD,
INC.

 

	By:
    	 	 
	Name:
    	Justin
    Schrieber	 
	Title:
    	CEO	 

 

[Signature
Page Securities Purchase Agreement]

 

    	22

     

    

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

Name
of Buyer: [              ]

 

Signature
of Authorized Signatory of Buyer: _______________

 

Name
of Authorized Signatory:

 

Title
of Authorized Signatory: 

 

Email
Address of Authorized Signatory:

 

Facsimile
Number of Authorized Signatory: 

 

Address
for Notice to Buyer:

 

Address
for Delivery of Securities to Buyer (if not same as address for notice):

 

Purchase
Price: $15,000,000.00

 

$15,000,000.00
principal amount of Debenture

 

Warrant
for 1,500,000 shares of Common Stock

 

EIN
Number of Buyer:

 

[Signature
Page - Securities Purchase Agreement]

 

    	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]